Lv1
40 积分 2024-11-21 加入
Unlocking the potential of the ACE2 /Ang‐(1–7)/Mas Axis in liver diseases: From molecular mechanisms to translational applications
1天前
已完结
Angiotensin‐converting enzyme inhibitors prevent liver‐related events in nonalcoholic fatty liver disease
1天前
已完结
Renin-angiotensin-aldosterone system inhibitor use improves clinical outcomes in patients with metabolic dysfunction–associated steatotic liver diseases: Target trial emulation using real-world data
1天前
已完结
The role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in managing metabolic dysfunction–associated steatotic liver disease
1天前
求助中
ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD?
1天前
已完结
Detection of Esophageal Varices and Prediction of Hepatic Decompensation in Unresectable Hepatocellular Carcinoma using AI
1个月前
已完结
Model of baseline clinicopathological features predicts non-resolution of drug-induced liver injury at 6 months
6个月前
已完结
Rivaroxaban to prevent complications of portal hypertension in cirrhosis: The CIRROXABAN study
7个月前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
8个月前
已完结
Phase 3 Trial of Semaglutide in Metabolic Dysfunction–Associated Steatohepatitis
9个月前
已完结
皖公网安备34019202002308
